Skip to content

Camp Based Multi-component Intervention for Families of Young Children With Type 1 Diabetes

Camp Based Multi-component Intervention for Families of Young Children With Type 1 Diabetes

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04279587
Enrollment
3
Registered
2020-02-21
Start date
2019-08-19
Completion date
2023-02-13
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type1diabetes

Brief summary

Eighteen preschool aged children and their families will attend structured, multidisciplinary, family-centered intensive education sessions over a 3-day weekend in a residential camp setting to address the unique challenges of managing type 1 diabetes mellitus in young children.

Detailed description

The invesigators propose to deliver a structured multidisciplinary family-centered intervention over a 3-day weekend. The intervention will be based at a regional camp. The proposed camp encounters aim to provide: * An opportunity for intensive education beyond that achievable in a single class, and without the unfavorable impacts of multiple weekday classes on family and work time. * Varied educational modalities including didactic sessions, practical demonstrations and role playing. * Close observation of each child throughout the day and night by experienced diabetes counselors and medical staff to identify and help correct maladaptive family behaviors. * A safe environment where parents can participate in group therapy sessions without child care worries. * An opportunity for age-appropriate child-centered educational and therapeutic activities. * An opportunity for families to form mutually-supportive friendships. * Fun weekends away where the parents have help caring for their diabetic children. The investigators will conduct this pilot study, which will enroll 18 preschool children age 3-5.5 years, with the goal of obtaining preliminary results for 15 subjects. The primary outcome, to be determined approximately one month before and 3 months after the camp session, is improvement in Hemoglobin A1c (HbA1c). Exploratory Hypotheses: Compared with pretreatment baseline, subjects attending a 3-day session at a family diabetes camp will improve: * HbA1c 3 months after the first camp session * Behavioral/QoL assessments, including the parents of young children version of the hypoglycemia fear survey (HFS-P-YC), the Behavioral Pediatrics Feeding Assessment Scale (BPFAS), and the general and diabetes modules of the PedsQL.

Interventions

BEHAVIORALResidential camp

Intensive education at a residential camp.

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 5 Years
Healthy volunteers
No

Inclusion criteria

* Age 3-5.5 years old (+/- 2 months) at the date of camp session they are eligible to join. * Child and Parents fluent in English * Type 1 diabetes mellitus diagnosed for at least 10 months previous to date of first camp they are eligible to join. * Taking insulin * Custodial parent or guardian (preferable both parents or guardians) willing to attend both session of camp and the activities scheduled for them. * Parent or guardian must sign consent before any study procedures are performed.

Exclusion criteria

* Neonatal diabetes (diagnosis in the first 3 months of life) or documented Monogenic Diabetes of Youth; i.e., a likely genetic form of diabetes rather than an autoimmune etiology. * Post-surgical diabetes (e.g., pancreatectomy for congenital hyperinsulinism). Such patients often cannot secrete glucagon, leading to a particularly severe inability to defend against hypoglycemia. * Other severe chronic disease (e.g., cancer, cystic fibrosis) which in the judgment of the investigator is likely to significantly affect glycemic control. * Patients cannot be taking systemic corticosteroids at enrollment because of adverse effects on glycemic control, but the investigators will not disqualify subjects who require such therapy during the study. Inhaled or topical corticosteroids are permissible. * Patients with hypothyroidism or hyperthyroidism must be clinically euthyroid and have free T4 and thyroid stimulating hormone within age-appropriate reference ranges at last medically indicated testing. Patients with out of range values may be retested after medication dose adjustment. * Developmental delay or behavioral disorder in the patient of sufficient severity, in the judgment of the investigator, to interfere with group activities. * Medical or psychiatric disorder in a parent of sufficient severity, in the judgment of the investigator, to interfere with group activities. * Celiac disease is not an exclusion criterion.

Design outcomes

Primary

MeasureTime frameDescription
Change in Hemoglobin A1c3 months3 month marker of glycemic control

Secondary

MeasureTime frameDescription
Change in PedsQL Family Impact Module3 monthsSurvey measure of impact the child's chronic disease has on the family
Change in PedsQL Pediatric Quality of Life Inventory3 monthsSurvey measure of quality of life
Change in Hypoglycemia Fear Survey3 monthsSurvey measure of hypoglycemia fear
Change in Behavioral Pediatrics Feeding Assessment3 monthsSurvey measure of child feeding habits

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026